April 14, 2022
--
As reported by IPWatchdog, Moderna is facing lawsuits in the United States from biotech firms, Arbutus Biopharma Corporation and Genevant Sciences GmbH.
Both companies allege that Moderna has infringed six of their U.S. patents relating to lipid nanoparticle (“LNP”) delivery technology. LNP delivery systems are crucial for mRNA therapies like Moderna’s COVID-19 vaccine by allowing treatments to bypass the human immune system without being destroyed.
Moderna has reportedly denied all allegations and vowed to vigorously defend itself against the claims made against it in court.
The plaintiffs in this action are seeking compensation, rather than an injunction, which is typically sought in such actions. If infringement is found, compensation through damages would likely be assessed through a “reasonable royalty”.
Authors: Zhiyao Chen and Awale Deria
